Frovatriptan (trade name Frova) is a triptan drug developed by Vernalis for the treatment of migraine headaches and for short term prevention of menstrual migraine. The product is licensed to Endo Pharmaceuticals in North America and Menarini in Europe.
|Elimination half-life||26 hours|
|CompTox Dashboard (EPA)|
|Chemical and physical data|
|Molar mass||243.310 g·mol−1|
|3D model (JSmol)|
Frovatriptan inhibits excessive dilation of arteries that supply blood to the head. It is available as 2.5 mg tablets.
Frovatriptan has mean terminal elimination half-life of approximately 26 hours, which is substantially longer than other triptans.
Mechanism of action
Frovatriptan is a 5HT receptor agonist, with high affinity for the 5-HT1B/1D receptors. It has no significant effects on the GABAA mediated channel activity and benzodiazepine binding sites.
Rare, but serious cardiac events have been reported in patients with risk factors predictive of CAD. These include: coronary artery vasospasm, transient myocardial ischemia, myocardial infarction, ventricular tachycardia and ventricular fibrillation.
Frovatriptan should not be given to patients with:
- Ischemic heart disease
- Cerebrovascular syndrome
- Peripheral vascular disease
- Uncontrolled hypertension
- Hemiplegic or basilar migraine
Frovatriptan is available only by prescription in the United States and Canada, where a secondary New Drug Approval (sNDA) was filed in July 2006.
- "Frova". Vernalis. Archived from the original on 2007-09-27. Retrieved 2007-11-28.
- "Patient Information Sheet -- Frovatriptan succinate (marketed as Frova)". Food and Drug Administration. July 2006. Archived from the original on 2007-09-29. Retrieved 2007-11-28.